Phase I trial of outpatient weekly docetaxel, carboplatin and concurrent thoracic radiation therapy for stage III unresectable non-small-cell lung cancer: a Vanderbilt cancer center affiliate network (VCCAN) trial

Choy, Hak; DeVore, Ronald A.; Hande, Kenneth R.; Porter, Lester; Rosenblatt, Paul; Slovis, Bonnie; LaPorte, K.; Shyr, Yu; Johnson, David H.

doi:10.1016/s0169-5002(01)00279-3

Cited by 27 publications

(17 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both esophagitis and neutropenia were found to be the DLT in a Phase I study of docetaxel in a 3-week cycle with concomitant thoracic RT. Choy et al also conducted a Phase I study to determine the DLT and MTD of docetaxel and carboplatin with concurrent thoracic RT [15][16][17][18] . The DLT was esophagitis, and the MTD of docetaxel was 20 mg/m2/wk with weekly carboplatin (AUC 2).…”

Section: Discussionmentioning

confidence: 99%

Phase I study to determine MTD of docetaxel and cisplatin with concurrent radiation therapy for stage III non-small cell lung cancer

Shi

et al. 2011

Chin. J. Cancer Res.

View full text Add to dashboard Cite

Objective: To evaluate the maximum tolerated dose (MTD) of docetaxel (DCT) and cisplatin (DDP) concurrently with three dimensional (3D) conformal radiotherapy or IMRT for patients with locally advanced non-small cell lung cancer (stage IIIa and IIIb) after 2-4 cycles of induction chemotherapy.Methods: Fourteen patients with histological/cytological proven stage III non-small-cell lung cancer were eligible. 3D or IMRT radiotherapy (60-70Gy in 30-35 fractions, 6-7weeks, 2 Gy/fraction) was delivered concurrently with cisplatin and docetaxel, 2 cycles during concurrent chemoradiotherapy (CCRT). The level I dosage was composed of 56 mg/m 2 DCT, on day 1 and 28mg/m 2 DDP, on day 1 and day 2. The level II was composed of 60 mg/m 2 DCT, on day 1 and 30 mg/ m 2 DDP, on day 1 and day 2. The level III was composed of 64 mg/m 2 DCT, on day 1 and 32 mg/ m 2 DDP, on day 1 and day 2.Results: Fourteen patients were allocated and finished concurrent chemoradiotherapy. The dose-limiting neutropenia was at the dose Level III (64 mg/m 2 ) and occurred in 2 of 5 patients. No dose limiting non-hematologic or hematologic toxicity occurred in the other patients.Conclusions: Patients with locally advanced non-small cell lung cancer may tolerate 60mg/m 2 docetaxel and 60mg/m 2 cisplatin for 2 cycles during concurrent radiotherapy after 2-3 cycles of induction chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Phase I study to determine MTD of docetaxel and cisplatin with concurrent radiation therapy for stage III non-small cell lung cancer

Shi

et al. 2011

Chin. J. Cancer Res.

View full text Add to dashboard Cite

show abstract

“…Three of these NSCLC studies [55][56][57] involved 57 patients who received weekly docetaxel, 20-40 mg/m 2 per dose, to a total of four to six doses over 5-6 weeks. The concurrent radiation therapy was given as five fractions per week to total doses ranging from 50 to 64 Gy.…”

Section: Single-agent Docetaxel Plus Radiotherapymentioning

confidence: 99%

“…Doses of docetaxel recommended for phase II studies consisted of four to six doses of 30 mg/m 2 over 5-6 weeks when used concurrently with irradiation. Although these were phase I studies, efficacy data from the first three studies included a median survival time of 15 months [55] and overall response rates of 47% [59] and 77% [56]. In one trial [56], complete tumor responses were reported in 8 of 30 patients (27%) and, in another study [58], there were two complete and six partial in-field responses in 20 patients (40%) with NSCLC.…”

Section: Single-agent Docetaxel Plus Radiotherapymentioning

confidence: 99%

“…Docetaxel plus carboplatin with concurrent radiotherapy has also been investigated in phase I and II studies in patients with stage III disease [57,[73][74][75]; one trial [76] assessed patients with early, resectable NSCLC (Table 3). Choy et al [57] (Fig.…”

Section: Docetaxel and Cisplatin Or Carboplatin Plus Radiotherapymentioning

confidence: 99%

“…Choy et al [57] (Fig. 2), and the authors recommended a weekly schedule of docetaxel, 20 mg/m 2 , with carboplatin, to an AUC of 2 mg/ml·min, and with standard radiation therapy to a total dose of 60 Gy over 6 weeks.…”

Section: Docetaxel and Cisplatin Or Carboplatin Plus Radiotherapymentioning

confidence: 99%

See 2 more Smart Citations

Docetaxel-Based Combined-Modality Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer

Scagliotti

Turrisi

2003

The Oncologist

View full text Add to dashboard Cite

The cytotoxic agent docetaxel not only has proven activity in non-small cell lung cancer-when used alone or in combination-but is also a potent radiosensitizer, and improved treatments are needed in all stages of this disease. In patients with locoregionally advanced (stage III) disease, docetaxel has shown efficacy with manageable toxicities when used alone or in combination with a platinum compound in a sequential manner before localized radical radiotherapy/surgery. Presently, therapeutic gains appear to be maximized by the use of concurrent chemotherapy and irradiation. This review focuses on research with combinations of docetaxel with either cisplatin or carboplatin and radiotherapy. Overall response and survival rates to date provide data worth pursuing.

show abstract

Chemoradiotherapy: Emerging treatment improvement strategies

Milas¹,

Mason²,

Liao³

et al. 2002

Head & Neck

View full text Add to dashboard Cite

Concurrent chemoradiotherapy, using standard chemotherapeutic agents, has emerged as an effective treatment for advanced cancer, but unfortunately at the expense of considerable increase in normal tissue toxicity. There are a number of potential emerging treatment strategies to further improve chemoradiotherapy. One consists of using newer chemotherapeutic drugs, which in preclinical studies are potent enhancers of tumor radioresponse. Another approach consists of targeting EGFR or COX-2 with selective inhibitors of these molecules.

show abstract

Phase I trial of outpatient weekly docetaxel, carboplatin and concurrent thoracic radiation therapy for stage III unresectable non-small-cell lung cancer: a Vanderbilt cancer center affiliate network (VCCAN) trial

Cited by 27 publications

References 36 publications

Phase I study to determine MTD of docetaxel and cisplatin with concurrent radiation therapy for stage III non-small cell lung cancer

Phase I study to determine MTD of docetaxel and cisplatin with concurrent radiation therapy for stage III non-small cell lung cancer

Docetaxel-Based Combined-Modality Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer

Chemoradiotherapy: Emerging treatment improvement strategies

Contact Info

Product

Resources

About